INSTI's For The Management of HIV-associated TB (INSIGHT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04734652

Recruitment Status : Active, not recruiting

First Posted : February 2, 2021

Last Update Posted : April 3, 2024

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborators:

Johns Hopkins University

National Institute of Allergy and Infectious Diseases (NIAID)

University of Cape Town

Medical Research Council, South Africa

Information provided by (Responsible Party):

Anushka Naidoo, Centre for the AIDS Programme of Research in South Africa

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Actual Primary Completion Date :	January 19, 2024
Estimated Study Completion Date :	August 31, 2024

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Naidoo A, Dooley KE, Naidoo K, Padayatchi N, Yende-Zuma N, Perumal R, Dorse G, Boodhram R, Osuala EC. INSTIs for the management of HIV-associated TB (INSIGHT study): a phase 2b study to evaluate the efficacy, safety and pharmacokinetics of a combination of bictegravir, emtricitabine and tenofovir alafenamide fumarate for the treatment of HIV-1 infection in patients with drug-susceptible tuberculosis on a rifampicin-based treatment regimen: a phase 2b open-label randomised controlled trial. BMJ Open. 2022 Nov 10;12(11):e067765. doi: 10.1136/bmjopen-2022-067765.

To Top